Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region
Authors:
Open Access
- 15 August 2020
- journal article
- research article
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 21 (1) , 1-7
Abstract
Background: Most patients treated with erenumab in clinical practice have chronic migraine (CM). We assessed the rate and possible predictors of conversion from CM to episodic migraine (EM) in a real-life study.Main body: We performed a subgroup analysis of patients treated with erenumab from January 2019 to February 2020 in the Abruzzo region, central Italy. Treatment was provided according to current clinical practice. For the purpose of the present study, we included patients fulfilling the definition of CM for the three months preceding erenumab treatment and with at least 6 months of follow-up after treatment. We assessed the rate of conversion to EM from baseline to Months 4–6 of treatment and during each month of treatment. To test the clinical validity of conversion to EM, we also assessed the decrease in monthly headache days (MHDs), acute medication days, and median headache intensity on a Numerical Rating Scale (NRS). We included in our study 91 patients with CM. At Months 4–6, 62 patients (68.1%) converted from CM to EM; the proportion of converters increased from Month 1 to Month 5. In the overall group of patients, median MHDs decreased from 26.5 (IQR 20–30) to 7.5 (IQR 5–16;P < 0.001) compared with baseline, while median acute medication days decreased from 21 (IQR 16–30) to 6 (IQR 3–10;P < 0.001) and median NRS scores decreased from 8 (IQR 7–9) to 6 (IQR 4–7;P < 0.001). Significant decreases were found both in converters and in non-converters. We found no significant predictors of conversion to EM among the patients’ baseline characteristics.Conclusions: In our study, two thirds of patients with CM converted to EM during 6 months of treatment with erenumab. MHDs, acute medication use, and headache intensity decreased regardless of conversion from CM to EM.Keywords
All Related Versions
Funding Information
- Novartis Pharma
This publication has 25 references indexed in Scilit:
- European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine preventionThe Journal of Headache and Pain, 2019
- The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical PracticeHeadache: The Journal of Head and Face Pain, 2018
- 12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of HeadachesThe Journal of Headache and Pain, 2018
- Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled studyCephalalgia, 2018
- Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd editionCephalalgia, 2018
- A Controlled Trial of Erenumab for Episodic MigraineNew England Journal of Medicine, 2017
- Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial designThe Journal of Headache and Pain, 2017
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trialThe Lancet Neurology, 2017
- When does chronic migraine strike? A clinical comparison of migraine according to the headache days suffered per monthCephalalgia, 2016
- Chronic migraine: risk factors, mechanisms and treatmentNature Reviews Neurology, 2016